Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BabyLux

Financiado

Cerrado

Launching the First Non Invasive Brain Monitoring System for the Early Detection...

Launching the First Non Invasive Brain Monitoring System for the Early Detection and Management of Encephalopathy In Preterm Babies Over the last two decades preterm babies (neonates with less than 37 weeks of gestational period) have rise tremendously reaching 15 million births worldwide in 2014, and the figures are growing. Anyhow, despite we have been succe... ver más

31/05/2017

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

HEMOPHOTONICS SL No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-05-31

SMEInst-01-2016-2017: Open Disruptive Innovation Scheme

I+D

Cerrada hace 8 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

APE An analyzer for preterm EEG 191K€ Cerrado

INFANS INtegrating Functional Assessment measures for Neonatal Safe... 4M€ Cerrado

PARENT PremAtuRe nEwborn motor and cogNitive impairmenTs Early dia... 4M€ Cerrado

PSI2010-18193 ANALISIS DE LA CORRELACION ENTRE VARIABLES FISIOLOGICAS Y CO... 30K€ Cerrado

BitMap Brain injury and trauma monitoring using advanced photonics 4M€ Cerrado

PID2021-129022OA-I00 BIOMARCADORES COMPUTACIONALES DE IMAGEN POR RESONANCIA MAGNE... 154K€ Cerrado

Duración del proyecto: 4 meses Fecha Inicio: 2017-01-29
Fecha Fin: 2017-05-31

Líder del proyecto

HEMOPHOTONICS SL No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Over the last two decades preterm babies (neonates with less than 37 weeks of gestational period) have rise tremendously reaching 15 million births worldwide in 2014, and the figures are growing. Anyhow, despite we have been successful at maintaining alive premature babies until their live it’s not at risk, we are failing at solving important side-problems. Preterm babies are at high risk of suffering encephalopathies (brain damage) during the artificial gestational stage on the neonatal intensive-care units (NICUs). In fact, about 20% of babies born before 6.5 months gestation experience lasting brain damage. This leads to lifelong disorders such as attention deficit, autism, cerebral paralysis, and hearing or visual impairments. To early detect cerebral damage in a precise manner it’s necessary to provide real time and accurate measures of cerebral oxygen metabolism and blood flow in the brain. This problem remains unsolved since current commercial solutions provide partial measurements or are extremely invasive. BabyLux will be the first device allowing early detect and manage encephalopathies in preterm-babies in a non-invasive and affordable manner by combining two leading photonic techniques. Our product fall within the sub-segment of monitoring equipment for NICUs, which is a € 1.200M market growing at a CARG of 6.5%.BabyLux will be sold at a first commercialization stage to pre-clinical markets (research institutions studying brain damage in neonates). We will proceed in such way since to gain credibility among scientific community, easing the entrance to clinical segments. At a second commercialization stage we will approach clinical segments, in particular hospitals with NICUs. This mixed business model will allow HemoPhotonics to achieve a turnover of € 13 M at 5 years after the project compilation. We are requesting a SMEI Phase 1 to further define and corroborate our business assumptions.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores